Based on a renewed importance recently attributed to bi- or multifunctional opioids, we report the synthesis and pharmacological evaluation of some analogues derived from our lead μ agonist / δ antagonist, H-Dmt-Tic-Gly-NH-Bzl. Our previous studies focused on the importance of the C-teminal benzyl function in the induction of such bifunctional activity. The introduction of some substituents in the para position of the phenyl ring (-Cl, -CH(3), partially -NO(2), inactive -NH(2)) was found to give a more potent μ agonist / antagonist effect associated with a relatively unmodified δ antagonist activity (pA(2) = 8.28-9.02). Increasing the steric hindrance of the benzyl group (using diphenylmethyl and tetrahydroisoquinoline functionalities) substantially maintained the μ agonist and δ antagonist activities of the lead compound. Finally and quite unexpectedly D-Tic2, considered as a wrong opioid message now; inserted into the reference compound in lieu of L-Tic, provided a μ agonist / δ agonist better than our reference ligand (H-Dmt-Tic-Gly-NH-Ph) and was endowed with the same pharmacological profile.
Based on a renewed importance recently attributed to bi- or multifunctional opioids, we report the synthesis and pharmacological evaluation of some analogues derived from our lead μ agonist / δ antagonist, H-Dmtn class="Chemical">-Tic-Gly-NH-Bzl. Our previous studies focused on the importance of the C-teminal benzyl function in the induction of such bifunctional activity. The introduction of some substituents in the para position of the phenyl ring (-Cl, -CH(3), partially -NO(2), inactive -NH(2)) was found to give a more potent μ agonist / antagonist effect associated with a relatively unmodified δ antagonist activity (pA(2) = 8.28-9.02). Increasing the steric hindrance of the benzyl group (using diphenylmethyl and tetrahydroisoquinoline functionalities) substantially maintained the μ agonist and δ antagonist activities of the lead compound. Finally and quite unexpectedly D-Tic2, considered as a wrong opioid message now; inserted into the reference compound in lieu of L-Tic, provided a μ agonist / δ agonist better than our reference ligand (H-Dmt-Tic-Gly-NH-Ph) and was endowed with the same pharmacological profile.
Authors: R B Rothman; J A Danks; A E Jacobson; T R Burke; K C Rice; F C Tortella; J W Holaday Journal: Eur J Pharmacol Date: 1986-05-13 Impact factor: 4.432
Authors: Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel Journal: Cancer Res Date: 2002-08-01 Impact factor: 12.701
Authors: Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg Journal: ACS Chem Biol Date: 2011-10-11 Impact factor: 5.100
Authors: Aaron M Bender; Nicholas W Griggs; Jessica P Anand; John R Traynor; Emily M Jutkiewicz; Henry I Mosberg Journal: ACS Chem Neurosci Date: 2015-05-13 Impact factor: 4.418
Authors: Henry I Mosberg; Larisa Yeomans; Aubrie A Harland; Aaron M Bender; Katarzyna Sobczyk-Kojiro; Jessica P Anand; Mary J Clark; Emily M Jutkiewicz; John R Traynor Journal: J Med Chem Date: 2013-02-27 Impact factor: 7.446
Authors: N Dietis; H Niwa; R Tose; J McDonald; V Ruggieri; M Filaferro; G Vitale; L Micheli; C Ghelardini; S Salvadori; G Calo; R Guerrini; D J Rowbotham; D G Lambert Journal: Br J Pharmacol Date: 2018-05-14 Impact factor: 8.739
Authors: Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg Journal: ACS Chem Neurosci Date: 2019-07-01 Impact factor: 4.418
Authors: András Váradi; Travis C Palmer; Nathan Haselton; Daniel Afonin; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Gina F Marrone; Attila Borics; Susruta Majumdar Journal: ACS Chem Neurosci Date: 2015-07-21 Impact factor: 4.418
Authors: Ruben S Vardanyan; James P Cain; Saghar Mowlazadeh Haghighi; Vlad K Kumirov; Mary I McIntosh; Alexander J Sandweiss; Frank Porreca; Victor J Hruby Journal: J Heterocycl Chem Date: 2016-06-01 Impact factor: 2.193